Top

Hepatology International

Published in:

01-07-2020 | Liver Transplantation | Consensus

Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations

Authors: George Lau, Manoj Sharma, APASL Covid-19 Task Force

Published in: Hepatology International | Issue 4/2020

Abstract

Background

Confronting a once-in-a-century pandemic with COVID-19, tremendous stress has been placed in all walks of life worldwide.

Aims

In order to enhance scientific information interflow in the arena of liver diseases in Asia–Pacific region during this difficult time, Asian-Pacific Association for the Study of the Liver (APASL) has taken the initiative to form the APASL COVID-19 Taskforce to formulate a clinical practice guidance in Hepatology, liver-related oncology, transplantation and conduct of clinical trials.

Methods

A taskforce with 22 key opinion leaders in Hepatology from 16 countries or administration regions in Asia–Pacific regions was formed and through intense interaction via webinar, this guidance was formulated. Based on scientific data and experiences, recommendations were made in the management of liver injury, liver transplantation, autoimmune diseases, chronic liver diseases, delivery of elective and emergency services and conduct of clinical trials.

Conclusions

This is the first consensus clinical guidance synthesized by APASL for our hepatologist and their allied medical personal.

https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-ncov). Accessed 16 Apr 2020.

Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med. 2003;139:493–8.CrossRefPubMed

Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-n CoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970–1.CrossRefPubMedPubMedCentral

Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis. 2020. https://doi.org/10.3201/eid2607.200282 (Epub ahead of print).CrossRefPubMedPubMedCentral

Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect. 2020. https://doi.org/10.1016/j.jinf.2020.03.041 (Epub ahead of print).CrossRefPubMedPubMedCentral

Luo S, Zhang X, Xu H. Don't overlook digestive symptoms in patients with 2019 novel coronavirus disease (COVID-19). Clin Gastroenterol Hepatol. 2020. https://doi.org/10.1016/j.cgh.2020.03.043 (Epub ahead of print).CrossRefPubMedPubMedCentral

https://www.cdc.gov/coronavirus/2019-ncov/community/organizations/cleaning-disinfection.html. Accessed 16 Apr 2020.

Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020. https://doi.org/10.1016/j.jinf.2020.04.021 (Epub ahead of print).CrossRefPubMedPubMedCentral

Ji D, Zhang D, Xu J, Chen Z, Yang T, Zhao P, et al. Prediction for progression risk in patients with COVID-19 pneumonia: the CALL score. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa414 (Epub ahead of print).CrossRefPubMed

10.

Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020. https://doi.org/10.1111/liv.14435 (Epub ahead of print).CrossRefPubMedPubMedCentral

11.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020. https://doi.org/10.1001/jama.2020.1585 (Epub ahead of print).CrossRefPubMedPubMedCentral

12.

Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. Characteristics of liver tests in COVID-19 patients. J Hepatol. 2020. https://doi.org/10.1016/j.jhep.2020.04.006.CrossRefPubMedPubMedCentral

13.

Wander P, Epstein M, Bernstein D. COVID-19 presenting as acute hepatitis. Am J Gastroenterol. 2020. https://doi.org/10.14309/ajg.0000000000000660 (Epub ahead of print).CrossRefPubMedPubMedCentral

14.

Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv. 2020. https://doi.org/10.1101/2020.02.03.931766.CrossRef

15.

Zhao B, Ni C, Gao R, Wang Y, Yang L, Wei J, et al. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. Protein Cell. 2020. https://doi.org/10.1007/s13238-020-00718-6 (Epub ahead of print).CrossRefPubMedPubMedCentral

16.

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med. 2020;382(18):1708–20.CrossRefPubMed

17.

Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. Zhonghua Bing Li Xue Za Zhi. 2020;49:E009 (in Chinese).

18.

Polakos NK, Cornejo JC, Murray DA, Wright KO, Treanor JJ, Crispe IN, et al. Kupffer cell dependent hepatitis occurs during influenza infection. Am J Pathol. 2006;168(4):1169–78.CrossRefPubMedPubMedCentral

19.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020. https://doi.org/10.1016/S2213-2600(20)30076-X (Epub ahead of print).CrossRefPubMedPubMedCentral

20.

Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020. https://doi.org/10.1016/S2213-2600(20),30216-2 (Epub ahead of print).CrossRefPubMedPubMedCentral

21.

Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844–7.CrossRefPubMedPubMedCentral

22.

Zhang XJ, Cheng X, Yan ZZ, Fang J, Wang X, Wang W, et al. An ALOX12-12- HETE-GPR31 signaling axis is a key mediator of hepatic ischemia-reperfusion injury. Nat Med. 2018;24:73–83. https://doi.org/10.1038/nm.4451.CrossRefPubMed

23.

24.

Tian S, Xiong Y, Liu H, Niu L, Guo J, Liao M, Xiao SY. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol. 2020. https://doi.org/10.1038/s41379-020-0536-x (Epub ahead of print).CrossRefPubMedPubMedCentral

25.

Boeckmans J, Rodrigues RM, Demuyser T, Piérard D, Vanhaecke T, Rogiers V. COVID-19 and drug-induced liver injury: a problem of plenty or a petty point? Arch Toxicol. 2020. https://doi.org/10.1007/s00204-020-02734-1 (Epub ahead of print).CrossRefPubMedPubMedCentral

26.

Massart J, Begriche K, Moreau C, Fromenty B. Role of non-alcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity. J Clin Transl Res. 2017;3(Suppl 1):212–32.PubMedPubMedCentral

27.

Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020. https://doi.org/10.1038/s41577-020-0308-3 (Epub ahead of print).CrossRefPubMedPubMedCentral

28.

Chen LF, Mo YQ, Jing J, Ma JD, Zheng DH, Dai L. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation. Int J Rheum Dis. 2017;20(7):859–69.CrossRefPubMed

29.

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2007016.CrossRefPubMedPubMedCentral

30.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2001282.CrossRefPubMedPubMedCentral

31.

Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;20:105949. https://doi.org/10.1016/j.ijantimicag.2020.105949.CrossRef

32.

Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020. https://doi.org/10.1016/j.eng.2020.03.007.CrossRefPubMed

33.

Wang YM, Zhang DY, Du GH, Du R, Zhang J, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020. https://doi.org/10.1016/S0140-6736(20)31022-9.CrossRefPubMedPubMedCentral

34.

Ji D, et al. Effect of COVID-19 on patients with compensated chronic liver diseases. Hepatol Int. 2020. (in press)

35.

Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y, Lau G. Implication of non-alcoholic fatty liver diseases (NAFLD) in patients with COVID-19: a preliminary analysis. J Hepatol. 2020. https://doi.org/10.1016/j.jhep.2020.03.044 (Epub ahead of print).CrossRefPubMedPubMedCentral

36.

Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1–98.CrossRefPubMed

37.

Wang JH, Chang KC, Kee KM, Chen PF, Yen YH, Tseng PL, et al. Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. Am J Gastroenterol. 2013;108:416–24.CrossRefPubMed

38.

Pangeli P, Bernardi M, Villanueva C, Francoz C, Mookerjee RP, Trebicka J, Krag A, et al. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–60.CrossRef

39.

Gu J, Han B, Wang J. COVID-19: gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology. 2020. https://doi.org/10.1053/j.gastro.2020.02.054 (Epub ahead of print).CrossRefPubMedPubMedCentral

40.

To KK-W, Tsang OT-Y, Chik-Yan Yip C, Chan K-H, Wu T-C, Chan JMC, et al. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa149 (Epub ahead of print).CrossRefPubMedPubMedCentral

41.

Soetikno R, Teoh AYB, Kaltenbach T, Lau JYW, Asokkumar R, Cabral-Prodigalidad P, et al. Considerations in performing endoscopy during the COVID-19 pandemic. Gastrointest Endosc. 2020. https://doi.org/10.1016/j.gie.2020.03.3758 (Epub ahead of print).CrossRefPubMedPubMedCentral

42.

de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–52.CrossRefPubMed

43.

Wang W, Xu Y Gao R, Lu R, Han K, Wu G et al (2020) Detection of SARS-Cov2 in different types of clinical specimens. JAMA. https://jamanetwork.com/on. Accessed 19 Apr 20

44.

Liu W, Tao ZW, Lei W, Ming-Li, Jing L, Shuang W, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Me J. 2020;133(9):1032–8.CrossRef

45.

Angelico R, Trapani S, Manzia TM, Lombardini L, Tisone G, Cardillo M. The COVID-19 outbreak in Italy: initial implications for organ transplantation programs. Am J Transplant. 2020. https://doi.org/10.1111/ajt.15904 (Epub ahead of print).CrossRefPubMed

46.

Boyarsky BJ, Chiang TP, Werbel WA, Durand CM, Avery RK, Getsin SN, et al. Early impact of COVID-19 on transplant center practices and policies in the United States. Am J Transplant. 2020. https://doi.org/10.1111/ajt.15915(Epub ahead of print).CrossRefPubMedPubMedCentral

47.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3 (Epub 2020 Mar 11).CrossRefPubMedPubMedCentral

48.

Garg S, Kim L, Whitaker M, O'Halloran A, Cummings C, Holstein R, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458–64. https://doi.org/10.15585/mmwr.mm6915e3.CrossRefPubMedPubMedCentral

49.

Xu K, Chen Y, Yuan J, Yi P, Ding C, Wu W, et al. Factors associated with prolonged viral RNA shedding in patients with COVID-19. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa351(Epub ahead of print).CrossRefPubMedPubMedCentral

50.

Zhong Z, Zhang Q, Xia H, Wang A, Liang W, Zhou W, et al. Clinical characteristics and immunosuppressants management of coronavirus disease 2019 in solid organ transplant recipients. Am J Transplant. 2020. https://doi.org/10.1111/ajt.15928 (Epub ahead of print).CrossRefPubMedPubMedCentral

51.

Fernández-Ruiz M, Andrés A, Loinaz C, Delgado JF, López-Medrano F, San Juan R, et al. COVID-19 in solid organ transplant recipients: a single-center case series from Spain. Am J Transplant. 2020. https://doi.org/10.1111/ajt.15929 (Epub ahead of print).CrossRefPubMedPubMedCentral

52.

Bhoori S, Rossi RE, Citterio D, Mazzaferro V. COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. Lancet Gastroenterol Hepatol. 2020. https://doi.org/10.1016/S2468-1253(20),30116-3 (Epub ahead of print).CrossRefPubMedPubMedCentral

53.

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4. https://doi.org/10.1016/S0140-6736(20)30628-0 (Epub 2020 Mar 16).CrossRefPubMedPubMedCentral

54.

Liu H, He X, Wang Y, Zhou S, Zhang D, Zhu J, He Q, et al. Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation. Hepatol Int. 2020. https://doi.org/10.1007/s12072-020-10043-z (Epub ahead of print).CrossRefPubMed

55.

Boettler T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep. 2020;2(3):100113. https://doi.org/10.1016/j.jhepr.2020.100113 (Epub ahead of print).CrossRefPubMedPubMedCentral

56.

Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, Pratt DS, Russo MW, Schilsky ML, Verna EC, Loomba R, Cohen DE, Bezerra JA, Reddy KR, Chung RT. AASLD clinical insights for hepatology and liver transplant providers during the covid-19 pandemic. Hepatology. 2020. https://doi.org/10.1002/hep.31281. Accessed 12 May 2020.CrossRefPubMed

57.

Transplant Society of Australia and New Zealand: COVID-19—National Transplantation and Donation Rapid Response Taskforce. https://www.tsanz.com.au/Website%20Update%20-%20COVID-19%20as%20at%2015%20April%202020%20FINAL.pdf. Accessed 25 Apr 2020.

58.

Lleo A, Invernizzi P, Lohse AW, Aghemo A, Carbone M. Highlights for management of patients with Autoimmune Liver Disease during COVID-19 pandemia. J Hepatol. 2020. https://doi.org/10.1016/j.jhep.2020.04.002 (Epub ahead of print).CrossRefPubMedPubMedCentral

59.

Meng H, Xiong R, He R, Lin W, Hao B, Zhang L, et al. CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China. J Infect. 2020. https://doi.org/10.1016/j.jinf.2020.04.004 (Epub ahead of print).CrossRefPubMedPubMedCentral

60.

Serper M, Cubell AW, Deleener ME, Casher TK, Rosenberg DJ, Whitebloom D, et al. Telemedicine in liver disease and beyond: can the COVID-19 crisis lead to action? Hepatology. 2020. https://doi.org/10.1002/hep.31276 (Epub ahead of print).CrossRefPubMed

61.

Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317–70.CrossRefPubMed

62.

Raturi M, Kusum A. The active role of a blood center in outpacing the transfusion transmission of COVID-19. Transfus Clin Biol. 2020;27(2):96–7.CrossRefPubMedPubMedCentral

63.

Shander A, Goobie SM, Warner MA, Aapro M, Bisbe E, Perez-Calatayud AA, et al. The essential role of patient blood management in a pandemic: a call for action. Anesth Analg. 2020. https://doi.org/10.1213/ANE.0000000000004844 (Epub ahead of print).CrossRefPubMedPubMedCentral

64.

Hirotsu Y, Maejima M, Nakajima M, Mochizuki H, Omata M. Environmental cleaning is effective for the eradication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in contaminated hospital rooms: a patient from the Diamond Princess cruise ship. Infect Control Hosp Epidemiol. 2020. https://doi.org/10.1017/ice.2020.144 (Epub ahead of print).CrossRefPubMedPubMedCentral

65.

The Japan Society for Transplantation (in Japanese): https://square.umin.ac.jp/jst-covid-19/images/guidance2.pdf. Accessed 22 Apr 2020.

66.

Kamboj M, Sepkowitz KA. Nosocomial infections in patients with cancer. Lancet Oncol. 2009;10:589–97.CrossRefPubMed

67.

Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–7. https://doi.org/10.1016/S1470-2045(20)30096-6.CrossRefPubMedPubMedCentral

68.

Clay JM, Parker MO. Alcohol use and misuse during the COVID-19 pandemic: a potential public health crisis? Lancet Public Health. 2020. https://doi.org/10.1016/S2468-2667(20),30088-8 (Epub ahead of print).CrossRefPubMedPubMedCentral

69.

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020. https://doi.org/10.1001/jama.2020.2648 (Epub ahead of print).CrossRefPubMedPubMedCentral

70.

Lippi G, de Oliveira MHS, Henry BM. Chronic liver disease is not associated with severity or mortality in Coronavirus disease 2019 (COVID-19): a pooled analysis. Eur J Gastroenterol Hepatol. 2020. https://doi.org/10.1097/MEG.0000000000001742 (Epub ahead of print).CrossRefPubMedCentral

71.

Chen X, Jiang Q, Ma Z, Ling J, Hu W, Cao Q, et al. Clinical characteristics of hospitalized patients with SARS-CoV-2 and hepatitis B virus co-infection. medRxiv. 2020. https://doi.org/10.1101/2020.03.23.20040733.CrossRefPubMedPubMedCentral

72.

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2002032 (Epub ahead of print).CrossRefPubMedPubMedCentral

73.

Ali S, Egunsola O, Babar ZUD, Hasan SS. Clinical trials in Asia: a World Health Organization database study. Perspect Clin Res. 2019;10(3):121–4. https://doi.org/10.4103/picr.PICR_109_18.CrossRefPubMedPubMedCentral

74.

Boettler T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, Berg T. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep. 2020;2(3):100113.CrossRefPubMedPubMedCentral

75.

COVID-19-Related Guidance Documents for Industry, FDA Staff, and Other Stakeholders. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-related-guidance-documents-industry-fda-staff-and-other-stakeholders. Accessed 25 Apr 2020.

Title: Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations
Authors: George Lau
Manoj Sharma
APASL Covid-19 Task Force
Publication date: 01-07-2020
Publisher: Springer India
Keywords: Liver Transplantation
Liver Transplantation
Hepatocellular Carcinoma
Liver Transplantation
Hepatocellular Carcinoma
COVID-19
Liver Transplantation
Liver Transplantation
Published in: Hepatology International / Issue 4/2020
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-020-10054-w

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Aims

Methods

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2020

Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population

Identification of prognostic claudins signature in hepatocellular carcinoma from a hepatocyte differentiation model

Utility of N-acetylcysteine in ischemic hepatitis in cirrhotics with acute variceal bleed: a randomized controlled trial

Distribution and clinical relevance of phospholipids in hepatocellular carcinoma

Viscoelastic test-based bleeding risk score reliably predicts coagulopathic bleeding in decompensated cirrhosis and ACLF patients

A novel, bedside, etiology specific prognostic model (Peds-HAV) in hepatitis A induced pediatric acute liver failure

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage